Vytrus Biotech Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	8.37	5.04	3.74	3.68	2.8
Revenue Growth (YoY)	65.95%	35.00%	1.48%	31.31%	64.49%
Cost of Revenue	0.91	0.52	0.48	0.4	0.29
Gross Profit	7.46	4.52	3.26	3.29	2.51
Selling, General & Admin	4.85	3.78	3.3	2.87	2.3
Depreciation & Amortization Expenses	0.97	0.83	0.73	0.69	0.58
Other Operating Expenses	-0.03	-0.02	-0.05	-0.04	-0.02
Total Operating Expenses	5.8	4.59	3.97	3.53	2.86
Operating Income	3.18	1	0.45	0.64	0.43
Interest Income	0.03	0.02	-	0.01	-
Interest Expense	-0.08	-0.12	-	-0.2	-0.12
Other Non-Operating Income (Expense)	-0	-0	-	-0	-0
Total Non-Operating Income (Expense)	-0.05	-0.1	-	-0.19	-0.12
Pretax Income	3.13	0.9	0.31	0.45	0.31
Provision for Income Taxes	0.23	-0.12	-0.24	-0.15	-0.14
Net Income	2.9	1.02	0.54	0.61	0.45
Net Income to Common	2.9	1.02	0.54	0.61	0.45
Net Income Growth	183.70%	87.36%	-9.96%	34.49%	107.48%
Shares Outstanding (Basic)	8	8	7	7	7
Shares Outstanding (Diluted)	8	8	7	7	7
Shares Change (YoY)	-	7.31%	-	1.64%	-
EPS (Basic)	0.38	0.13	0.08	0.09	0.06
EPS (Diluted)	0.38	0.13	0.08	0.09	0.06
EPS Growth	192.31%	62.50%	-11.11%	50.00%	100.00%
Free Cash Flow	2.89	1.74	0.76	0.61	0.23
Free Cash Flow Growth	65.63%	128.46%	25.94%	166.43%	-
Free Cash Flow Per Share	0.38	0.23	0.11	0.09	0.03
Gross Margin	89.16%	89.63%	87.29%	89.25%	89.51%
Operating Margin	37.99%	19.92%	12.16%	17.51%	15.32%
Profit Margin	34.60%	20.24%	14.58%	16.44%	16.05%
FCF Margin	34.48%	34.55%	20.41%	16.45%	8.11%
EBITDA	4.16	1.83	1.18	1.34	1.01
EBITDA Margin	49.63%	36.36%	31.56%	36.29%	35.88%
EBIT	3.18	1	0.45	0.64	0.43
EBIT Margin	37.99%	19.92%	12.16%	17.51%	15.32%
Effective Tax Rate	7.34%	-13.23%	-76.74%	-33.67%	-45.56%